HomeCompareNCRBF vs MRK

NCRBF vs MRK: Dividend Comparison 2026

NCRBF yields 3.81% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $31.2K in total portfolio value
10 years
NCRBF
NCRBF
● Live price
3.81%
Share price
$31.57
Annual div
$1.20
5Y div CAGR
-0.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.6K
Annual income
$476.50
Full NCRBF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — NCRBF vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNCRBFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NCRBF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NCRBF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NCRBF
Annual income on $10K today (after 15% tax)
$324.14/yr
After 10yr DRIP, annual income (after tax)
$405.03/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MRK beats the other by $7,923.39/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NCRBF + MRK for your $10,000?

NCRBF: 50%MRK: 50%
100% MRK50/50100% NCRBF
Portfolio after 10yr
$41.2K
Annual income
$5,137.32/yr
Blended yield
12.48%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

NCRBF
No analyst data
Altman Z
3.3
Piotroski
4/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NCRBF buys
0
MRK buys
0
No recent congressional trades found for NCRBF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNCRBFMRK
Forward yield3.81%2.76%
Annual dividend / share$1.20$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-0.2%32.7%
Portfolio after 10y$25.6K$56.8K
Annual income after 10y$476.50$9,798.13
Total dividends collected$4.3K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NCRBF vs MRK ($10,000, DRIP)

YearNCRBF PortfolioNCRBF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,081$380.58$11,206$366.19$125.00MRK
2$12,250$393.33$12,650$502.35$400.00MRK
3$13,513$405.56$14,407$694.19$894.00MRK
4$14,876$417.28$16,585$967.82$1.7KMRK
5$16,346$428.46$19,342$1,363.89$3.0KMRK
6$17,929$439.12$22,913$1,947.19$5.0KMRK
7$19,633$449.24$27,662$2,823.89$8.0KMRK
8$21,466$458.84$34,159$4,173.35$12.7KMRK
9$23,437$467.92$43,337$6,308.80$19.9KMRK
10$25,554$476.50$56,776$9,798.13$31.2KMRK

NCRBF vs MRK: Complete Analysis 2026

NCRBFStock

Nippon Carbon Co., Ltd. engages in the manufacture and sale of carbon products in Japan. It offers carbon fiber products, including molded heat insulating materials for high temperature furnaces; CARBORON, a soft felt used in a range of heat insulators for high temperature furnaces; C/C Composite, a lightweight carbon material used in heat resistant composite structural members, high temperature furnace materials, trays, jigs, etc.; and CARBEST, a carbon fiber packing material. The company also provides specialty carbon products, such as isotropic graphite, a graphite material; high purity treatment graphite used for manufacturing device components for silicon semiconductors, compound semiconductors, and optical fibers; carbon products for mechanical components that are used in various fields of science, including electronics, machinery, and the metallurgy industry; VESCOAT, a silicon carbide coated product used for silicon semiconductor, LED, and manufacturing device components for optical fibers; and SC CARBON sliding composites. In addition, it offers artificial graphite electrodes for use in high-power electric arc furnaces; silicon carbide continuous fibers, such as Nicalon, Hi-Nicalon, and Hi-Nicalon TypeS for use as reinforcement fibers in ceramic composite materials, plastic composite materials, and others; and lithium ion secondary batteries used for cellular and smart phones, NBPC, tablet terminals, power tools, hybrid automobiles, and electric automobiles. Further, the company provides impervious graphite RESBON, a corrosion-resistant material; NICABEADS, which are surface-coated micro bead-shape materials; and NICAFILM, a flexible graphite sheet made from natural graphite. The company was incorporated in 1915 and is headquartered in Tokyo, Japan.

Full NCRBF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this NCRBF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NCRBF vs SCHDNCRBF vs JEPINCRBF vs ONCRBF vs KONCRBF vs MAINNCRBF vs JNJNCRBF vs ABBVNCRBF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.